Skip to content

Restoring Immune Homeostasis

An Integrated Strategy to Correcting Immune System Dysregulation

Homeostasis Disrupted

Complex biological systems interact with the environment to achieve homeostasis – the physiological stability needed to sustain life. From basic functions that maintain normal body temperature regulation to calibrated immune signaling to fight disease, our bodies seek equilibrium to survive and thrive. Autoimmune and inflammatory diseases result from dysregulation of the healthy immune response, rooted in either the adaptive or innate immune systems. They include many debilitating and life-threatening conditions, affecting every organ system and causing dramatically decreased quality of life and significant morbidity and mortality for tens of millions of patients worldwide. For many autoimmune and inflammatory diseases, treatment options are inadequate or absent altogether. Systemic immunomodulators can help manage some inflammatory and autoimmune diseases, but they often deliver inadequate efficacy and are associated with treatment-limiting side effects that can be severe.

Insight, Expertise, Approach

To meet the need for therapies that safely address underlying immune dysregulation, Q32 Bio has developed an integrated portfolio of therapies to modulate the innate and adaptive immune responses. Our team’s mission is to bring safer, more efficacious therapeutics to patients suffering from a wide range of devastating autoimmune and inflammatory diseases, starting with those rooted in the complement system and interleukin-7 (IL-7) signaling pathways. In pursuit of our bold vision, Q32 Bio has assembled leaders in the field of immunology uniquely positioned to develop novel biologics based on the body’s innate and adaptive immune systems. Our lead molecules include therapeutic fusion proteins that deliver negative regulators of complement activation directly to disease-affected tissues and a monoclonal antibody antagonist of the interleukin-7 receptor (IL-7R).

Our Pipeline

Q32 Bio has advanced a strong clinical and discovery pipeline based on the body’s innate and adaptive immune systems and the drive to restore immune homeostasis in patients with severe inflammatory and autoimmune diseases.

Our Team

With an expert team comprised of highly skilled drug developers and immunology experts from the biotech/biopharma industry, Q32 Bio is well-positioned to deliver on its mission to bring new therapeutics to patients with severe inflammatory and autoimmune diseases.


Q32 Bio Appoints Experienced Biopharmaceutical Leader Mark Iwicki as Chairman of Board of Directors

Cambridge, Mass. (December 22nd, 2020) – Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of industry leader Mark Iwicki as Chairman of their Board of Directors. Mr. Iwicki will succeed Dr. David Grayzel as Chairman. Dr. Grayzel, an Atlas Venture partner and co-founder of Q32, will continue as a Director. Read More >

Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis

Cambridge, Mass. (October 29, 2020) – Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation, today announced the completion of a $60 million Series B financing co-led by OrbiMed Advisors and Acorn Bioventures. The company also announced the commencement of a Phase 1 clinical trial evaluating its best-in-class IL-7R antibody ADX-914, a significant milestone marking Q32 Bio’s entry into clinical-stage development. Read More >

Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity

Proprietary tissue-targeted complement platform and best-in-class IL-7R antibody technology to treat patients with severe autoimmune and inflammatory disease; clinical trials begin in 2020 Read More >

Q32 Bio is a Proud Supporter of Life Science Cares

Read More >